

Polymyalgia rheumatica – 2012

Polymyalgia rheumatica en 2012

Literatur / Références

- Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Dierssen T, Llorca J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. *Arthritis Rheum.* 2009;61(10):1454–61.
- Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. *Clin Exp Rheumatol.* 2000;18(4 Suppl 20):9–11.
- Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. *Arthritis Rheum.* 1983;26(10):1214–9.
- Pereira LS, Yoon MK, Hwang TN, Hong JE, Ray K, Porco T, McCulley TJ. Giant cell arteritis in Asians: a comparative study. *Br J Ophthalmol.* 2011;95(2):214–6.
- Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. *Lancet.* 2008;372(9634):234–45.
- Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. *Ann Intern Med.* 1995;123(3):192–4.
- Weyand CM, Ma-Krupa W, Pryshchep O, Gröschel S, Bernardino R, Goronzy JJ. Vascular dendritic cells in giant cell arteritis. *Ann N Y Acad Sci.* 2005;1062:195–208.
- Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. *Nat Rev Rheumatol.* 2012;8(9):509–21.
- Soriano A et al. Polymyalgia rheumatica in 2011. *Best Practice & Research Clinical Rheumatology.* 2012;26:91–104.
- Cantini F et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease and severity in polymyalgia rheumatica: a prospective follow-up study. *Semin Arthritis Rheum.* 2000;30(1):17.
- Schmidt et al. Procalcitonin at the onset of giant cell arteritis and polymyalgia rheumatica: the GRACG prospective study. *Rheumatology.* 2009;48(2):158–9.
- Dasgupta B, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann. Rheum Dis.* 2012;71:484–92.
- Blockmans D, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. *Rheumatology (Oxford).* 2007;46:672–7.
- Salvarani C et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? *Ann Intern Med.* 2002;137(4):232.
- Karassa FB, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. *Ann Intern Med.* 2005;142(5):359.
- Sidhom OA, Basalae M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. *Arch Intern Med.* 1993;153(17):2043–5.
- Aubry-Rozier B, Lamy O, Dudler J. Prevention of cortisone-induced osteoporosis: who, when and what?. *Rev Med Suisse.* 2010;6(235):307–13.
- Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. *J Rheumatol.* 2005;32(1):65–73.
- Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? *Ann Rheum Dis.* 1996;55(4):218–23.
- Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, Montecucco C: Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2004;141(7):493–500.
- Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. *Int J Clin Pract.* 2012;66(9):906–9.
- Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. *Ann Intern Med.* 2007;146(9):621–30.
- Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. *Ann Intern Med.* 2007;146(9):631–9.
- Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. *Arthritis Res Ther.* 2010;12(5):R176.

25. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. *J Rheumatol*. 2003;30(4):760–3.
26. Migliore A, Massafra U, Carloni E, Padalino C, Martin S, Lasaracina F, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. *Eur Rev Med Pharmacol Sci*. 2005;9(6):373–8.
27. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. *J Rheumatol*. 2010;37(5):1075–6.
28. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. *Swiss Med Wkly*. 2011;141:w13156.
29. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. *Rheumatology (Oxford)*. 2012;51(1):151–6.